After a fresh cash injection, Step is ready to take STP938 for the treatment of T-cell blood cancers into Phase I trials in February.
Step Pharma has taken a big stride towards getting its first-in-class CTPS1 inhibitor into the clinic after closing a €35m series B financing.
The French biotech, which raised €14.5m with its series A in 2017, has attracted a couple of new backers in...
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
